 MORRISVILLE, N.C., Nov. 18, 2020 GLOBE NEWSWIRE -- Syneos Health, Inc. Nasdaq: SYNH the Company or Syneos Health, the only fully integrated biopharmaceutical solutions organization combining a CRO Contract Research Organization and a CCO Contract Commercial Organization, today announced the upsizing and pricing of an offering of 600.0 million aggregate principal amount of 3.625 senior notes due 2029 the Notes, an upsize of 100.0 million over the amount previously announced. The Notes were priced at par value and will bear an interest rate of 3.625 per annum. The Notes are being offered in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended the Securities Act. The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Companys subsidiaries. Syneos Health expects to close the offering of the Notes on November 24, 2020, subject to the satisfaction of customary closing conditions. 